IDH mutation analysis in glioma patients by CADMA compared with SNaPshot assay and two immunohistochemical methods
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F19%3AE0107866" target="_blank" >RIV/00843989:_____/19:E0107866 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/18:A1901TQT RIV/61989592:15110/19:73588666
Result on the web
<a href="https://link.springer.com/article/10.1007%2Fs12253-018-0413-9" target="_blank" >https://link.springer.com/article/10.1007%2Fs12253-018-0413-9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s12253-018-0413-9" target="_blank" >10.1007/s12253-018-0413-9</a>
Alternative languages
Result language
angličtina
Original language name
IDH mutation analysis in glioma patients by CADMA compared with SNaPshot assay and two immunohistochemical methods
Original language description
Mutations in IDH1/2 genes are a marker of good prognosis for glioma patients, associated with low grade gliomas and secondary glioblastomas. Immunohistochemistry and Sanger sequencing are current standards for IDH1/2 genotyping while many other methods exist. The aim of this study was to validate Competitive amplification of differentially melting amplicons (CADMA) PCR for IDH genotyping by comparison with SNaPshot assay and two immunohistochemical methods. In our study, 87 glioma patients (46 from Olomouc and 41 from Ostrava) were analyzed. IDH1/2 mutations in native bioptical samples were analyzed at DNA level by CADMA and SNaPshot while IDH1 mutations in FFPE samples were analyzed at protein level by two IHC methods. CADMA PCR sensitivity for IDH1 was 96.4% and specificity 100% for 86 concluded samples. SNaPshot assay sensitivity was 92.9% and specificity of 100% for 85 concluded samples. IHC in the laboratory no. 2 reached sensitivity 85.7% and specificity 100% for 86 concluded samples. IHC in the laboratory no. 4 reached sensitivity of 96.4% and specificity of 79.7% in 74 concluded samples. Only one IDH2 mutation was found by SNaPshot while CADMA yielded false negative result. In conclusion, CADMA is a valid method for IDH1 p.(R132H) testing with higher sensitivity than SNaPshot assay. Also, molecular genetic methods of IDH1 testing from native samples were more robust than IHC from FFPE.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pathology & oncology research
ISSN
1219-4956
e-ISSN
1532-2807
Volume of the periodical
25
Issue of the periodical within the volume
3
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
8
Pages from-to
971-978
UT code for WoS article
000475558500016
EID of the result in the Scopus database
2-s2.0-85044189432